BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Meridia sibutramine: Phase III data

The double-blind, U.S. Phase III SCOUT trial in 10,744 overweight or obese patients >=55 years old with pre-existing cardiovascular disease and/or Type II diabetes showed that Meridia led to a significantly higher rate of primary outcome events, which included non-fatal MI, non-fatal stroke, resuscitation after cardiac arrest or CV death vs. placebo after a mean treatment duration of 3.4 years (11.4% vs. 10%,...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >